ArticleBrain and behavior2026
Retinal Pathology and Synucleinopathy in the Visual Pathway of α-Synuclein Preformed Fibril Mouse Model of Parkinson's Disease.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundVisual dysfunction is a common nonmotor manifestation of Parkinson's disease (PD) that may precede motor symptoms. This study aimed to characterize the early preformed fibril (PFF) mouse model of PD.
methodsMale C57BL/6J mice received intrastriatal injections of α-synuclein (α-syn) PFFs or phosphate-buffered saline. Visual function was evaluated at 3 and 6 months postinjection using pattern visual evoked potentials (PVEPs) and the visual cliff test. Retinal morphology and protein expression were assessed by hematoxylin-eosin staining, immunofluorescence, and Western blot analysis for phosphorylated α-syn (pS129), tyrosine hydroxylase (TH), glial fibrillary acidic protein (GFAP), and Iba1. Pathological α-syn distribution in the visual pathway and association cortices was examined by fluorescence microscopy.
resultsAt 3 months, PFF-injected mice showed prolonged PVEP latency and reduced amplitude, indicating early visual pathway dysfunction, which worsened by 6 months. Retinal structure was preserved, but p-α-syn accumulation appeared in ganglion cells, accompanied by reduced TH expression and activation of microglia and Müller glia. The pSer129-immunoreactive structures were detected in the visual cortex and visual association cortices, including frontal, parietal, temporal, and amygdaloid regions.
conclusionsFunctional and pathological alterations in the visual system emerge before motor deficits in α-syn PFF-injected mice. Early retinal and cortical synucleinopathy may underlie prodromal visual dysfunction and serve as potential biomarkers for early PD diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.